

Yen-Shen Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1178232/publications.pdf>

Version: 2024-02-01

131
papers

7,070
citations

117625

34
h-index

62596

80
g-index

137
all docs

137
docs citations

137
times ranked

9606
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	7.0	18
2	Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 629-637.	2.5	6
3	Abstract P2-10-09: Oxysterol profiling in breast adipose tissue identifies brassicasterol and 24-hydroxycholesterol as breast cancer risk predictors. <i>Cancer Research</i> , 2022, 82, P2-10-09-P2-10-09.	0.9	0
4	Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies. <i>Cancer Research</i> , 2022, 82, P5-13-18-P5-13-18.	0.9	0
5	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022, 82, PD2-05-PD2-05.	0.9	2
6	Abstract P2-01-09: Clinical impact of ESR1 mutation ctDNA on survival outcome is dependent on PI3KCA/TP53 ctDNA mutation status. <i>Cancer Research</i> , 2022, 82, P2-01-09-P2-01-09.	0.9	0
7	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. <i>BMC Medicine</i> , 2022, 20, 105.	5.5	60
8	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2 ⁺ Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	7.0	90
9	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 408-417.	7.0	21
10	Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 669-678.	2.8	16
11	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 418-428.	7.0	16
12	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	5.0	15
13	Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 193-207.	2.0	34
14	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021, 14, 1015-1025.	3.1	2
15	BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)â€”Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1023-1023.	1.6	49
16	High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. <i>Npj Breast Cancer</i> , 2021, 7, 88.	5.2	8
17	Genomic Profiling of Premenopausal HR+ and HER2 ⁺ Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420.	3.0	15
18	Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 665-676.	2.5	15

#	ARTICLE	IF	CITATIONS
19	Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. <i>Frontiers in Oncology</i> , 2021, 11, 700722.	2.8	12
20	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	3.6	7
21	Anti-HER2 antibody prolongs overall survival disproportionately more than progression-free survival in HER2-Positive metastatic breast cancer patients. <i>Breast</i> , 2021, 59, 211-220.	2.2	2
22	Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2~ Advanced Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 8179-8189.	1.9	2
23	Response to Sung, Rosenberg, and Yang. <i>Journal of the National Cancer Institute</i> , 2020, 112, 547-548.	6.3	0
24	Mortality of Pregnancy Following Breast Cancer Diagnoses in Taiwanese Women. <i>Oncologist</i> , 2020, 25, e252-e258.	3.7	4
25	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ~ 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	1.6	355
26	Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094306.	3.2	44
27	A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women. <i>Environment International</i> , 2020, 142, 105850.	10.0	48
28	Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. <i>Oncologist</i> , 2020, 25, e16-e23.	3.7	40
29	Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival. <i>Journal of Neuro-Oncology</i> , 2020, 148, 165-172.	2.9	17
30	Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1009-1009.	1.6	34
31	CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tasetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tasetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1111-TPS1111.	1.6	2
32	Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS599-TPS599.	1.6	6
33	Induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases: Results of a randomized phase II A-PLUS trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1082-1082.	1.6	0
34	Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. <i>Scientific Reports</i> , 2019, 9, 10898.	3.3	5
35	Treating HR+/HER2~ breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	2.5	29
36	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019, 15, 2489-2501.	2.4	8

#	ARTICLE	IF	CITATIONS
37	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 307-316.	27.0	656
38	Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1929-1940.	27.0	1,582
39	Insights Into Breast Cancer in the East vs the West. <i>JAMA Oncology</i> , 2019, 5, 1489.	7.1	90
40	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1298-1306.	6.3	83
41	PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1333-1338.	1.7	24
42	In-depth gene expression analysis of premenopausal patients with HR+/HER2 ⁻ advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1018-1018.	1.6	5
43	Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 1084-1084.	1.6	5
44	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2 ⁻ advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA1008-LBA1008.	1.6	19
45	The interplay of adiposity, metabolic factors, and tumor infiltrating lymphocytes in an East Asian breast cancer cohort. <i>Journal of Clinical Oncology</i> , 2019, 37, e14207-e14207.	1.6	0
46	Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. <i>Analytica Chimica Acta</i> , 2018, 1019, 93-102.	5.4	50
47	A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 242-247.	1.3	4
48	Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women. <i>Cancer Prevention Research</i> , 2018, 11, 227-236.	1.5	31
49	Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer. <i>European Radiology</i> , 2018, 28, 4860-4870.	4.5	9
50	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 904-915.	10.7	648
51	Effect of glucocorticoid use on survival in patients with stage III breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 225-234.	2.5	8
52	Association of pregnancy and mortality in women diagnosed with breast cancer: A Nationwide Population Based Study in Taiwan. <i>International Journal of Cancer</i> , 2018, 143, 2416-2424.	5.1	14
53	Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 1047-1047.	1.6	1
54	Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 6583-6593.	3.7	19

#	ARTICLE	IF	CITATIONS
55	Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. <i>Scientific Reports</i> , 2017, 7, 9842.	3.3	25
56	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
57	Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. <i>Oncotarget</i> , 2016, 7, 8310-8320.	1.8	83
58	Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. <i>European Journal of Cancer</i> , 2016, 60, 107-116.	2.8	8
59	Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1â€² and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 3860-3869.	1.5	29
60	Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer. <i>Scientific Reports</i> , 2016, 6, 21374.	3.3	17
61	A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. <i>BMC Cancer</i> , 2016, 16, 466.	2.6	23
62	Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 243-248.	1.7	17
63	Tailor the adjuvant hormonal manipulation for premenopausal breast cancer patients. <i>Translational Cancer Research</i> , 2016, 5, S380-S384.	1.0	0
64	TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. <i>Scientific Reports</i> , 2015, 5, 17879.	3.3	11
65	Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1407-1420.	3.4	20
66	High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. <i>PLoS ONE</i> , 2015, 10, e0124908.	2.5	9
67	Associations between Medical Conditions and Breast Cancer Risk in Asians: A Nationwide Population-Based Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0143410.	2.5	34
68	A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. <i>BMC Cancer</i> , 2015, 15, 299.	2.6	56
69	Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 1851-1858.	7.0	72
70	Clinical significance of LKB1 protein and gene expression in breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11538-e11538.	1.6	0
71	Randomized study of tailored neoadjuvant chemotherapy according to the expression of tau, topo II ±, and ERCC1 versus standard chemotherapy in HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1025-1025.	1.6	0
72	Distinct Clinicopathological Features and Prognosis of Emerging Young-Female Breast Cancer in an East Asian Country: A Nationwide Cancer Registry-Based Study. <i>Oncologist</i> , 2014, 19, 583-591.	3.7	44

#	ARTICLE	IF	CITATIONS
73	No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 135-142.	2.5	11
74	Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. <i>Histopathology</i> , 2014, 65, 328-339.	2.9	35
75	Quantification of target analytes in various biofluids using a postcolumn infused-internal standard method combined with matrix normalization factors in liquid chromatography-electrospray ionization mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1358, 85-92.	3.7	12
76	Abstract 2984: Normalization of tumor vasculature by anti-angiogenesis therapy in metastatic tumor: A clinical study to determine the timing and effect. <i>Cancer Research</i> , 2014, 74, 2984-2984.	0.9	3
77	Does chemotherapy schedule matter when combining with bevacizumab? A stratified meta-analysis of randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2014, 32, 1076-1076.	1.6	2
78	Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. <i>Journal of Neuro-Oncology</i> , 2013, 115, 61-70.	2.9	9
79	The first two lines of chemotherapy for anthracycline-naïve metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines. <i>Breast</i> , 2013, 22, 1148-1154.	2.2	3
80	Differential expression of ubiquitin carboxy-terminal hydrolase L1 in breast carcinoma and its biological significance. <i>Human Pathology</i> , 2013, 44, 1838-1848.	2.0	12
81	Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. <i>Journal of Clinical Pathology</i> , 2013, 66, 140-145.	2.0	15
82	The Impact of Diabetes Mellitus on Prognosis of Early Breast Cancer in Asia. <i>Oncologist</i> , 2012, 17, 485-491.	3.7	37
83	Hashimoto's Encephalopathy As the Cause of Deteriorating Consciousness During Treatment of Leptomeningeal Carcinomatosis From Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e358-e359.	1.6	0
84	Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. <i>Journal of Human Genetics</i> , 2012, 57, 130-138.	2.3	21
85	Radiosensitizing Effect of a Phenylbutyrate-Derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e181-e189.	0.8	22
86	Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. <i>Histopathology</i> , 2012, 61, 78-87.	2.9	38
87	Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2012, 82, 59-66.	1.9	29
88	Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. <i>BMC Cancer</i> , 2012, 12, 620.	2.6	16
89	The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. <i>International Journal of Cancer</i> , 2012, 130, 2629-2637.	5.1	47
90	Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1079-1079.	1.6	19

#	ARTICLE	IF	CITATIONS
91	Estimation of maximum tolerated dose and minimum efficient dose of BP-C1 in the treatment of stage IV breast cancer patients: A phase I response surface pathway designed study.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11022-e11022.	1.6	2
92	The first two lines of chemotherapy for anthracycline-naïve metastatic breast cancer: A comparative study of efficacy between anthracyclines and nonanthracyclines.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1061-1061.	1.6	0
93	The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer. <i>Academic Radiology</i> , 2011, 18, 212-219.	2.5	7
94	Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 345-351.	2.5	98
95	Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1257-1263.	2.3	8
96	Î²B kinases increase Myc protein stability and enhance progression of breast cancer cells. <i>Molecular Cancer</i> , 2011, 10, 53.	19.2	25
97	Cisplatin as an active treatment in zoledronate-refractory hypercalcemia. <i>Annals of Oncology</i> , 2011, 22, 1244-1246.	1.2	2
98	Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?. <i>Journal of Clinical Pathology</i> , 2011, 64, 781-787.	2.0	10
99	Axillary vs Sentinel Lymph Node Dissection for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2288.	7.4	6
100	Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. <i>Journal of Zhejiang University: Science B</i> , 2010, 11, 1-9.	2.8	12
101	The prevalence and assessment of ErbB2-positive breast cancer in Asia. <i>Cancer</i> , 2010, 116, 5348-5357.	4.1	17
102	Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 286-293.	1.3	27
103	Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 999-1013.	1.3	20
104	O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. <i>Lung Cancer</i> , 2010, 68, 484-490.	2.0	29
105	Unique features of breast cancer in Asian women—Breast cancer in Taiwan as an example. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 300-303.	2.5	42
106	Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. <i>Cancer Letters</i> , 2010, 298, 195-203.	7.2	20
107	Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1807-1814.	2.5	103
108	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 5820-5828.	7.0	35

#	ARTICLE	IF	CITATIONS
109	Locoregional Therapy Improves Survival for Metastatic Breast Cancer Patients? Benefit Remains Questionable!. <i>Journal of Clinical Oncology</i> , 2009, 27, e179-e179.	1.6	1
110	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. <i>Journal of Biological Chemistry</i> , 2009, 284, 11121-11133.	3.4	79
111	Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1077-1085.	10.7	29
112	Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I and operable stage III Taiwanese breast cancer patients. <i>Breast</i> , 2008, 17, 646-653.	2.2	14
113	Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells. <i>Cancer Research</i> , 2008, 68, 6698-6707.	0.9	109
114	NF- κ B p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 376, 283-287.	2.1	23
115	OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species-Related Autophagy in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 9348-9357.	0.9	131
116	FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through Activation of Protein Kinase C δ Signaling. <i>Cancer Research</i> , 2008, 68, 1204-1212.	0.9	99
117	Histone Deacetylase Inhibitors in Cancer Therapy. , 2008, , 381-398.		0
118	Pneumatosis Coli After Etoposide Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1623-1625.	1.6	17
119	Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation. <i>Cancer Research</i> , 2007, 67, 5318-5327.	0.9	179
120	Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. <i>Hepatology</i> , 2007, 46, 1119-1130.	7.3	84
121	Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. <i>Lung Cancer</i> , 2006, 53, 303-310.	2.0	38
122	Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 874-879.	2.8	9
123	Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF- κ B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. <i>Journal of Endocrinology</i> , 2006, 188, 311-319.	2.6	19
124	Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. <i>Oncology</i> , 2005, 69, 88-95.	1.9	19
125	Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. <i>World Journal of Gastroenterology</i> , 2005, 11, 5283.	3.3	18
126	Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. <i>World Journal of Gastroenterology</i> , 2005, 11, 6373.	3.3	25

#	ARTICLE	IF	CITATIONS
127	Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. <i>Physics in Medicine and Biology</i> , 2004, 49, 3593-3602.	3.0	74
128	Recent advances in the management of primary breast cancers. <i>Journal of the Formosan Medical Association</i> , 2004, 103, 579-98.	1.7	11
129	Basal levels and patterns of anticancer drug-induced activation of nuclear factor- κ B (NF- κ B), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. <i>Biochemical Pharmacology</i> , 2002, 63, 1709-1716.	4.4	159
130	Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma. <i>Cancer</i> , 2002, 95, 2044-2050.	4.1	10
131	Phthalate Exposure, Metabolism Capability, and Breast Cancer Risk: Case-Control Analysis Nested in a Large-Scale Long-Term Follow-Up Cohort. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0